Karan Topiwala
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Karan Topiwala has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
- Smit D. Patel
Department of Neurosurgery, Saint Francis Health System, Tulsa, OK
4 shared publications - Mark J. Alberts
Hartford HealthCare, Hartford, Connecticut, USA (M.J.A.)
3 shared publications Ramachandra Tummala
Department of Neurological Surgery, University of Minnesota, Minneapolis, MN, USA
3 shared publicationsAndrew Grande
Department of Neurosurgery, University of Minnesota, Minneapolis, MN, USA
2 shared publications- Bharathi Dasan Jagadeesan
Department of Radiology, University of Minnesota, Minneapolis, MN, USA
2 shared publications Bharathi Jagadeesan
Department of Neurological Surgery, University of Minnesota, Minneapolis, MN, USA
2 shared publications
Latest Publications
- Open Access
- 25 November 2023
- Published by Elsevier in Radiology Case Reports
- Vol. 19  (2) , 642-646
Percutaneous n-butyl cyanoacrylate embolization of cervical metastatic disease via an anterolateral approach
- 25 November 2023
- Published by Elsevier in Radiology Case Reports
- Vol. 19  (2) , 642-646
Open AccessPercutaneous n-butyl cyanoacrylate embolization of cervical metastatic disease via an anterolateral approach
- 26 October 2022
- Published by SAGE Publications in Interventional Neuroradiology
- Vol. 30  (2) , 288-292
Trans-radial spinal angiography: A single-center experience
Introduction: Spinal angiography (SpAn) is the gold standard for diagnosis of spinal dural fistulas and arteriovenous malformations. A complete spinal angiogram necessitates the interrogation of the segmental arteries arising from the aorta at every level as well, the internal iliac; and median sacral arteries at the caudal end; and the cervical vasculature at the cranial end. SpAn has traditionally been performed with transfemoral arterial access and could be challenging. Of late, transradial arterial access has emerged as a popular alternative for endovascular surgical Neuroradiology (ESN) procedures including SpAn. However, there is paucity of the literature regarding transradial access for spinal angiography. Methods: After IRB approval, records and imaging were reviewed in a series of patients who underwent SpAn at our institution. Results: A total of nine spinal angiograms were performed via transradial access in a consecutive series of eight patients between July 2019 and December 2020 at our institution. Eight of these were diagnostic SpAn's, and one patient underwent SpAn with transradial approach for the treatment of a type I spinal dural arteriovenous fistula. No complications occurred during or subsequent to the procedures. Conclusion: SpAn can be successfully and safely accomplished via transradial access. This approach appears to provide a stable method for interventions, as well.
- 26 October 2022
- Published by SAGE Publications in Interventional Neuroradiology
- Vol. 30  (2) , 288-292
Trans-radial spinal angiography: A single-center experience
Introduction: Spinal angiography (SpAn) is the gold standard for diagnosis of spinal dural fistulas and arteriovenous malformations. A complete spinal angiogram necessitates the interrogation of the segmental arteries arising from the aorta at every level as well, the internal iliac; and median sacral arteries at the caudal end; and the cervical vasculature at the cranial end. SpAn has traditionally been performed with transfemoral arterial access and could be challenging. Of late, transradial arterial access has emerged as a popular alternative for endovascular surgical Neuroradiology (ESN) procedures including SpAn. However, there is paucity of the literature regarding transradial access for spinal angiography. Methods: After IRB approval, records and imaging were reviewed in a series of patients who underwent SpAn at our institution. Results: A total of nine spinal angiograms were performed via transradial access in a consecutive series of eight patients between July 2019 and December 2020 at our institution. Eight of these were diagnostic SpAn's, and one patient underwent SpAn with transradial approach for the treatment of a type I spinal dural arteriovenous fistula. No complications occurred during or subsequent to the procedures. Conclusion: SpAn can be successfully and safely accomplished via transradial access. This approach appears to provide a stable method for interventions, as well.
- 30 May 2022
- Published by SAGE Publications in Interventional Neuroradiology
- Vol. 30  (1) , 80-85
BOBBY balloon guide catheter thrombectomy in large-vessel occlusion stroke: Initial experience
Background and Purpose: Nonrandomized studies have found Balloon Guide Catheter (BGC) use to improve technical and functional outcomes in patients undergoing mechanical thrombectomy (MT). Materials and Methods: We performed a retrospective analysis on prospectively collected data of consecutive ischemic stroke patients undergoing MT at our institution (December 2020-October 2021). Interventions where BOBBY BGC (BBGC, MicroVentionTM, Aliso Viejo, CA) was used were identified. Baseline demographics and clinico-radiographic characteristics were retrospectively collected and analysed using descriptive statistics. Results: A total of 43 patients received BBGC-MT (male: female = 26:17, median age 72 years [IQR 62-82]). The most common occlusion site was the middle cerebral artery (MCA) (60.4%). Over half (51.2%) received intravenous thrombolytics. The BBGC tracked well over tortuous aortic arches (type II 34.8%, type III 16.3%), with median arteriotomy-to-perfusion time of 29 min (IQR 20-46). Thromboaspiration was used as first-line MT technique in 69.7% cases, with 1 (IQR 1-2) median MT pass achieving modified TICI (thrombolysis in cerebral ischemia) scores of 3 and 2b/3 in 74.4% and 95.3% respectively. Our overall first pass effect (FPE, defined as mTICI 3 after firs-pass) and modified FPE (defined as, mTICI 2b/3 after first-pass) rates were 51.1% and 79.1% respectively, with rates of 92.3% and 100% respectively when stentretriever and thromboaspiration were combined. The median reduction in National Institutes of Health Stroke Scale (NIHSS) was 9 (IQR 4–15, p < 0.0001), with a median 90-day modified Rankin Score (mRS) of 1.5 (IQR 0-2). Conclusions: BOBBY BGC use resulted in a high first-pass effect rate and may contribute towards improved functional outcomes.
- 30 May 2022
- Published by SAGE Publications in Interventional Neuroradiology
- Vol. 30  (1) , 80-85
BOBBY balloon guide catheter thrombectomy in large-vessel occlusion stroke: Initial experience
Background and Purpose: Nonrandomized studies have found Balloon Guide Catheter (BGC) use to improve technical and functional outcomes in patients undergoing mechanical thrombectomy (MT). Materials and Methods: We performed a retrospective analysis on prospectively collected data of consecutive ischemic stroke patients undergoing MT at our institution (December 2020-October 2021). Interventions where BOBBY BGC (BBGC, MicroVentionTM, Aliso Viejo, CA) was used were identified. Baseline demographics and clinico-radiographic characteristics were retrospectively collected and analysed using descriptive statistics. Results: A total of 43 patients received BBGC-MT (male: female = 26:17, median age 72 years [IQR 62-82]). The most common occlusion site was the middle cerebral artery (MCA) (60.4%). Over half (51.2%) received intravenous thrombolytics. The BBGC tracked well over tortuous aortic arches (type II 34.8%, type III 16.3%), with median arteriotomy-to-perfusion time of 29 min (IQR 20-46). Thromboaspiration was used as first-line MT technique in 69.7% cases, with 1 (IQR 1-2) median MT pass achieving modified TICI (thrombolysis in cerebral ischemia) scores of 3 and 2b/3 in 74.4% and 95.3% respectively. Our overall first pass effect (FPE, defined as mTICI 3 after firs-pass) and modified FPE (defined as, mTICI 2b/3 after first-pass) rates were 51.1% and 79.1% respectively, with rates of 92.3% and 100% respectively when stentretriever and thromboaspiration were combined. The median reduction in National Institutes of Health Stroke Scale (NIHSS) was 9 (IQR 4–15, p < 0.0001), with a median 90-day modified Rankin Score (mRS) of 1.5 (IQR 0-2). Conclusions: BOBBY BGC use resulted in a high first-pass effect rate and may contribute towards improved functional outcomes.
- 1 February 2022
- Published by Wolters Kluwer Health in Neurology
- Vol. 98  (5) , 188-198
Ischemic Stroke and Pulmonary Arteriovenous Malformations
The potential of covert pulmonary arteriovenous malformations (PAVMs) to cause early onset, preventable ischemic strokes is not well known to neurologists. This is evident by their lack of mention in serial American Heart Association/American Stroke Association (AHA/ASA) Guidelines and the single case report biased literature of recent years. We performed PubMed and Cochrane database searches for major studies on ischemic stroke and PAVMs published from January 1, 1974, through April 3, 2021. This identified 24 major observational studies, 3 societal guidelines, 1 nationwide analysis, 3 systematic reviews, 21 other review/opinion articles, and 18 recent (2017–2021) case reports/series that were synthesized. Key points are that patients with PAVMs have ischemic stroke a decade earlier than routine stroke, losing 9 extra healthy life-years per patient in the recent US nationwide analysis (2005–2014). Large-scale thoracic CT screens of the general population in Japan estimate PAVM prevalence to be 38/100,000 (95% confidence interval 18–76), with ischemic stroke rates exceeding 10% across PAVM series dating back to the 1950s, with most PAVMs remaining undiagnosed until the time of clinical stroke. Notably, the rate of PAVM diagnoses doubled in US ischemic stroke hospitalizations between 2005 and 2014. The burden of silent cerebral infarction approximates to twice that of clinical stroke. More than 80% of patients have underlying hereditary hemorrhagic telangiectasia. The predominant stroke mechanism is paradoxical embolization of platelet-rich emboli, with iron deficiency emerging as a modifiable risk factor. PAVM-related ischemic strokes may be cortical or subcortical, but very rarely cause proximal large vessel occlusions. Single antiplatelet therapy may be effective for secondary stroke prophylaxis, with dual antiplatelet or anticoagulation therapy requiring nuanced risk–benefit analysis given their risk of aggravating iron deficiency. This review summarizes the ischemic stroke burden from PAVMs, the implicative pathophysiology, and relevant diagnostic and treatment overviews to facilitate future incorporation into AHA/ASA guidelines.
- 1 February 2022
- Published by Wolters Kluwer Health in Neurology
- Vol. 98  (5) , 188-198
Ischemic Stroke and Pulmonary Arteriovenous Malformations
The potential of covert pulmonary arteriovenous malformations (PAVMs) to cause early onset, preventable ischemic strokes is not well known to neurologists. This is evident by their lack of mention in serial American Heart Association/American Stroke Association (AHA/ASA) Guidelines and the single case report biased literature of recent years. We performed PubMed and Cochrane database searches for major studies on ischemic stroke and PAVMs published from January 1, 1974, through April 3, 2021. This identified 24 major observational studies, 3 societal guidelines, 1 nationwide analysis, 3 systematic reviews, 21 other review/opinion articles, and 18 recent (2017–2021) case reports/series that were synthesized. Key points are that patients with PAVMs have ischemic stroke a decade earlier than routine stroke, losing 9 extra healthy life-years per patient in the recent US nationwide analysis (2005–2014). Large-scale thoracic CT screens of the general population in Japan estimate PAVM prevalence to be 38/100,000 (95% confidence interval 18–76), with ischemic stroke rates exceeding 10% across PAVM series dating back to the 1950s, with most PAVMs remaining undiagnosed until the time of clinical stroke. Notably, the rate of PAVM diagnoses doubled in US ischemic stroke hospitalizations between 2005 and 2014. The burden of silent cerebral infarction approximates to twice that of clinical stroke. More than 80% of patients have underlying hereditary hemorrhagic telangiectasia. The predominant stroke mechanism is paradoxical embolization of platelet-rich emboli, with iron deficiency emerging as a modifiable risk factor. PAVM-related ischemic strokes may be cortical or subcortical, but very rarely cause proximal large vessel occlusions. Single antiplatelet therapy may be effective for secondary stroke prophylaxis, with dual antiplatelet or anticoagulation therapy requiring nuanced risk–benefit analysis given their risk of aggravating iron deficiency. This review summarizes the ischemic stroke burden from PAVMs, the implicative pathophysiology, and relevant diagnostic and treatment overviews to facilitate future incorporation into AHA/ASA guidelines.
- 1 January 2022
- Published by Elsevier in Journal of Stroke and Cerebrovascular Diseases
- Vol. 31  (1) , 106170
Patterns and Predictors of Extra-Corporeal Membrane Oxygenation Related Cerebral Microbleeds
- 1 January 2022
- Published by Elsevier in Journal of Stroke and Cerebrovascular Diseases
- Vol. 31  (1) , 106170
Patterns and Predictors of Extra-Corporeal Membrane Oxygenation Related Cerebral Microbleeds
- 1 December 2021
- Published by Wolters Kluwer Health in Stroke
- Vol. 52  (12) , 3970-3977
Outcomes Among Patients With Reversible Cerebral Vasoconstriction Syndrome: A Nationwide United States Analysis
Background and Purpose: Reversible cerebral vasoconstriction syndrome (RCVS) is a well-established cause of stroke, but its demographics and outcomes have not been well delineated. Methods: Analysis of the United States Nationwide Inpatient Sample database (2016–2017) to characterize the frequency of hospitalizations for RCVS, demographic features, inpatient mortality, and discharge outcomes. Results: During the 2-year study period, 2020 patients with RCVS were admitted to Nationwide Inpatient Sample hospitals, representing 0.02 cases per 100 000 national hospitalizations. The mean age at admission was 47.6 years, with 85% under 65 years of age, and 75.5% women. Concomitant neurological diagnoses during hospitalization included ischemic stroke (17.1%), intracerebral hemorrhage (11.0%), subarachnoid hemorrhage (32.7%), seizure disorders (6.7%), and reversible brain edema (13.6%). Overall, 70% of patients were discharged home, 29.7% discharged to a rehabilitation facility or nursing home and 0.3% died before discharge. Patient features independently associated with the poor outcome of discharge to another facility or death were advanced age (odds ratio [OR], 1.04 [95% CI, 1.03–1.04]), being a woman (OR, 2.45 [1.82–3.34]), intracerebral hemorrhage (OR, 2.91 [1.96–4.31]), ischemic stroke (OR, 5.72 [4.32–7.58]), seizure disorders (OR, 2.61 [1.70–4.00]), reversible brain edema (OR, 6.26 [4.41–8.89]), atrial fibrillation (OR, 2.97 [1.83–4.81]), and chronic kidney disease (OR, 3.43 [2.19–5.36]). Conclusions: Projected to the entire US population, >1000 patients with RCVS are hospitalized each year, with the majority being middle-aged women, and about 300 required at least some rehabilitation or nursing home care after discharge. RCVS-related inpatient mortality is rare.
- 1 December 2021
- Published by Wolters Kluwer Health in Stroke
- Vol. 52  (12) , 3970-3977
Outcomes Among Patients With Reversible Cerebral Vasoconstriction Syndrome: A Nationwide United States Analysis
Background and Purpose: Reversible cerebral vasoconstriction syndrome (RCVS) is a well-established cause of stroke, but its demographics and outcomes have not been well delineated. Methods: Analysis of the United States Nationwide Inpatient Sample database (2016–2017) to characterize the frequency of hospitalizations for RCVS, demographic features, inpatient mortality, and discharge outcomes. Results: During the 2-year study period, 2020 patients with RCVS were admitted to Nationwide Inpatient Sample hospitals, representing 0.02 cases per 100 000 national hospitalizations. The mean age at admission was 47.6 years, with 85% under 65 years of age, and 75.5% women. Concomitant neurological diagnoses during hospitalization included ischemic stroke (17.1%), intracerebral hemorrhage (11.0%), subarachnoid hemorrhage (32.7%), seizure disorders (6.7%), and reversible brain edema (13.6%). Overall, 70% of patients were discharged home, 29.7% discharged to a rehabilitation facility or nursing home and 0.3% died before discharge. Patient features independently associated with the poor outcome of discharge to another facility or death were advanced age (odds ratio [OR], 1.04 [95% CI, 1.03–1.04]), being a woman (OR, 2.45 [1.82–3.34]), intracerebral hemorrhage (OR, 2.91 [1.96–4.31]), ischemic stroke (OR, 5.72 [4.32–7.58]), seizure disorders (OR, 2.61 [1.70–4.00]), reversible brain edema (OR, 6.26 [4.41–8.89]), atrial fibrillation (OR, 2.97 [1.83–4.81]), and chronic kidney disease (OR, 3.43 [2.19–5.36]). Conclusions: Projected to the entire US population, >1000 patients with RCVS are hospitalized each year, with the majority being middle-aged women, and about 300 required at least some rehabilitation or nursing home care after discharge. RCVS-related inpatient mortality is rare.
- 1 July 2021
- Published by Wolters Kluwer Health in Stroke
- Vol. 52  (7) , E311-E315
Ischemic Stroke in Patients With Pulmonary Arteriovenous Fistulas
Background and Purpose: Pulmonary arteriovenous fistulas (PAVFs) are a treatable cause of acute ischemic stroke (AIS), not mentioned in current American Heart/Stroke Association guidelines. PAVFs are recognized as an important complication of hereditary hemorrhagic telangiectasia. Methods: The prevalence of PAVF and hereditary hemorrhagic telangiectasia among patients admitted with AIS in the United States (2005–2014) was retrospectively studied, utilizing the Nationwide Inpatient Sample database. Clinical factors, morbidity, mortality, and management were compared in AIS patients with and without PAVF/hereditary hemorrhagic telangiectasia. Results: Of 4 271 910 patients admitted with AIS, 822 (0.02%) were diagnosed with PAVF. Among them, 106 of 822 (12.9%) were diagnosed with hereditary hemorrhagic telangiectasia. The prevalence of PAVF per million AIS admissions rose from 197 in 2005 to 368 in 2014 ( P trend , 0.026). Patients with PAVF were younger than AIS patients without PAVF (median age, 57.5 versus 72.5 years), had lower age-adjusted inpatient morbidity (defined as any discharge other than home; 39.6% versus 46.9%), and had lower in-hospital case fatality rates (1.8% versus 5.1%). Multivariate analyses identified the following as independent risk markers (odds ratio [95% CI]) for AIS in patients with PAVF: hypoxemia (8.4 [6.3–11.2]), pulmonary hemorrhage (7.9 [4.1–15.1]), pulmonary hypertension (4.3 [4.1–15.1]), patent foramen ovale (4.2 [3.5–5.1]), epistaxis (3.7 [2.1–6.8]), venous thrombosis (2.6 [1.9–3.6]), and iron deficiency anemia (2 [1.5–2.7]). Patients with and without PAVF received intravenous thrombolytics at a similar rate (5.9% versus 5.8%), but those with PAVF did not receive mechanical thrombectomy (0% versus 0.7%). Conclusions: Pulmonary arteriovenous fistula–related ischemic stroke represents an important younger demographic with a unique set of stroke risk markers, including treatable conditions such as causal PAVFs and iron deficiency anemia.
- 1 July 2021
- Published by Wolters Kluwer Health in Stroke
- Vol. 52  (7) , E311-E315
Ischemic Stroke in Patients With Pulmonary Arteriovenous Fistulas
Background and Purpose: Pulmonary arteriovenous fistulas (PAVFs) are a treatable cause of acute ischemic stroke (AIS), not mentioned in current American Heart/Stroke Association guidelines. PAVFs are recognized as an important complication of hereditary hemorrhagic telangiectasia. Methods: The prevalence of PAVF and hereditary hemorrhagic telangiectasia among patients admitted with AIS in the United States (2005–2014) was retrospectively studied, utilizing the Nationwide Inpatient Sample database. Clinical factors, morbidity, mortality, and management were compared in AIS patients with and without PAVF/hereditary hemorrhagic telangiectasia. Results: Of 4 271 910 patients admitted with AIS, 822 (0.02%) were diagnosed with PAVF. Among them, 106 of 822 (12.9%) were diagnosed with hereditary hemorrhagic telangiectasia. The prevalence of PAVF per million AIS admissions rose from 197 in 2005 to 368 in 2014 ( P trend , 0.026). Patients with PAVF were younger than AIS patients without PAVF (median age, 57.5 versus 72.5 years), had lower age-adjusted inpatient morbidity (defined as any discharge other than home; 39.6% versus 46.9%), and had lower in-hospital case fatality rates (1.8% versus 5.1%). Multivariate analyses identified the following as independent risk markers (odds ratio [95% CI]) for AIS in patients with PAVF: hypoxemia (8.4 [6.3–11.2]), pulmonary hemorrhage (7.9 [4.1–15.1]), pulmonary hypertension (4.3 [4.1–15.1]), patent foramen ovale (4.2 [3.5–5.1]), epistaxis (3.7 [2.1–6.8]), venous thrombosis (2.6 [1.9–3.6]), and iron deficiency anemia (2 [1.5–2.7]). Patients with and without PAVF received intravenous thrombolytics at a similar rate (5.9% versus 5.8%), but those with PAVF did not receive mechanical thrombectomy (0% versus 0.7%). Conclusions: Pulmonary arteriovenous fistula–related ischemic stroke represents an important younger demographic with a unique set of stroke risk markers, including treatable conditions such as causal PAVFs and iron deficiency anemia.
- 1 December 2020
- Published by Elsevier in Journal of Stroke and Cerebrovascular Diseases
- Vol. 29  (12) , 105301
Novel GDF2 Gene Mutation Associated with Pulmonary Arteriovenous Malformation
- 1 December 2020
- Published by Elsevier in Journal of Stroke and Cerebrovascular Diseases
- Vol. 29  (12) , 105301
Novel GDF2 Gene Mutation Associated with Pulmonary Arteriovenous Malformation
- Open Access
- 27 August 2020
- Published by Springer Nature in Cureus
- Vol. 12  (8)
Cauda Equina Syndrome in Neurosarcoidosis
Neurosarcoidosis (NS) is a mimicker of many infectious, neoplastic, and inflammatory diseases. It most commonly involves the cranial nerves followed by meninges, ventricles, hypothalamic-pituitary axis, spinal cord, and brainstem/cerebellum. While NS myelopathy has been increasingly recognized, pathophysiological/prognostic and management principles in NS-mediated cauda equina (CE) and conus medullaris (CM) syndromes, which constitute a small and rare minority of this subset, remain elusive. We present the case of a 49-year-old Hispanic man who developed a peripheral facial palsy and primary hypogonadism within a span of 12 months and eventually got diagnosed with NS after he presented with CE syndrome. We also performed an extensive literature review, with a discussion on the underlying pathophysiology and current management recommendations for NS-mediated CE/CM syndrome. CE/CM syndromes in a middle-aged man should prompt the consideration of NS as a possible differential diagnosis. While steroid responsive, the majority of NS-CE/CM patients are left with residual neurodeficits with quick relapses when steroids are tapered, making the case for early institution of immunosuppressive therapies.
- 27 August 2020
- Published by Springer Nature in Cureus
- Vol. 12  (8)
Open AccessCauda Equina Syndrome in Neurosarcoidosis
Neurosarcoidosis (NS) is a mimicker of many infectious, neoplastic, and inflammatory diseases. It most commonly involves the cranial nerves followed by meninges, ventricles, hypothalamic-pituitary axis, spinal cord, and brainstem/cerebellum. While NS myelopathy has been increasingly recognized, pathophysiological/prognostic and management principles in NS-mediated cauda equina (CE) and conus medullaris (CM) syndromes, which constitute a small and rare minority of this subset, remain elusive. We present the case of a 49-year-old Hispanic man who developed a peripheral facial palsy and primary hypogonadism within a span of 12 months and eventually got diagnosed with NS after he presented with CE syndrome. We also performed an extensive literature review, with a discussion on the underlying pathophysiology and current management recommendations for NS-mediated CE/CM syndrome. CE/CM syndromes in a middle-aged man should prompt the consideration of NS as a possible differential diagnosis. While steroid responsive, the majority of NS-CE/CM patients are left with residual neurodeficits with quick relapses when steroids are tapered, making the case for early institution of immunosuppressive therapies.
- Open Access
- 17 February 2020
- Published by BMJ in Stroke and Vascular Neurology
- Vol. 5  (3) , 308-310
Staged endovascular reconstruction of complex traumatic intracranial carotid artery dissection
A 32-year-old-woman presented with traumatic facial injuries from a horseback riding incident. She was found to have a Glasgow Coma Score of 3T, left eyelid ptosis with a fixed-dilated pupil and a flaccid right upper extremity. CT angiogram of the head showed complex craniofacial injuries, including a transverse fracture transecting the clivus and the left petrous temporal bone, with SAH in the suprasellar cistern. There was a bilateral engorgement of the superior ophthalmic veins, suggestive of bilateral CCF formations. Digital subtraction angiography (DSA) showed a left petrocavernous internal carotid artery dissection (ICAD). MRI of the brain demonstrated multiple embolic infarcts in the left middle cerebral artery (MCA) territory, despite therapeutic anticoagulation with heparin. Follow-up DSA 1 week later showed bilateral multifocal internal carotid artery (ICA) and vertebral artery dissections, bilateral direct CCFs and cavernous ICA PAs. Because of progressing morphological distortion (figure 1), a flexible LVIS Jr. stent was placed at the anterior genu of the left cavernous ICA to provide a scaffold for the more rigid 3.5Ă—20.0 mm self-expanding Wingspan stent (petrous ICA to distal cavernous ICA), covering the neck of the PA followed by its coil embolisation. Five days after coiling, a 5 mm residual sac was noted in the PA with extension of the left ICAD up to the ICA terminus (figure 2). The latter was treated with another 3.5Ă—23.0 mm LVIS Jr. stent (from left the M1 MCA up to the dural junction of the left ICA). Eleven days after coiling, the PA had increased up to 15Ă—14 mm and was treated with three PED constructs deployed in a pseudo-telescoping manner from the petrous ICA to the supraclinoid ICA causing immediate flow diversion (figure 3). While maintained on a heparin drip during the procedure, she was transitioned to eptifibatide and aspirin after stent placement, and then on DAPT (aspirin (81 mg) and clopidogrel (75 mg) daily) 4 weeks from initial stenting.
- 17 February 2020
- Published by BMJ in Stroke and Vascular Neurology
- Vol. 5  (3) , 308-310
Open AccessStaged endovascular reconstruction of complex traumatic intracranial carotid artery dissection
A 32-year-old-woman presented with traumatic facial injuries from a horseback riding incident. She was found to have a Glasgow Coma Score of 3T, left eyelid ptosis with a fixed-dilated pupil and a flaccid right upper extremity. CT angiogram of the head showed complex craniofacial injuries, including a transverse fracture transecting the clivus and the left petrous temporal bone, with SAH in the suprasellar cistern. There was a bilateral engorgement of the superior ophthalmic veins, suggestive of bilateral CCF formations. Digital subtraction angiography (DSA) showed a left petrocavernous internal carotid artery dissection (ICAD). MRI of the brain demonstrated multiple embolic infarcts in the left middle cerebral artery (MCA) territory, despite therapeutic anticoagulation with heparin. Follow-up DSA 1 week later showed bilateral multifocal internal carotid artery (ICA) and vertebral artery dissections, bilateral direct CCFs and cavernous ICA PAs. Because of progressing morphological distortion (figure 1), a flexible LVIS Jr. stent was placed at the anterior genu of the left cavernous ICA to provide a scaffold for the more rigid 3.5Ă—20.0 mm self-expanding Wingspan stent (petrous ICA to distal cavernous ICA), covering the neck of the PA followed by its coil embolisation. Five days after coiling, a 5 mm residual sac was noted in the PA with extension of the left ICAD up to the ICA terminus (figure 2). The latter was treated with another 3.5Ă—23.0 mm LVIS Jr. stent (from left the M1 MCA up to the dural junction of the left ICA). Eleven days after coiling, the PA had increased up to 15Ă—14 mm and was treated with three PED constructs deployed in a pseudo-telescoping manner from the petrous ICA to the supraclinoid ICA causing immediate flow diversion (figure 3). While maintained on a heparin drip during the procedure, she was transitioned to eptifibatide and aspirin after stent placement, and then on DAPT (aspirin (81 mg) and clopidogrel (75 mg) daily) 4 weeks from initial stenting.